Wedbush Estimates PepGen’s Q1 Earnings (NASDAQ:PEPG)

PepGen Inc. (NASDAQ:PEPG) – Equities researchers at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for shares of PepGen in a report released on Monday, February 24th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.54) per share for the quarter, up from their previous forecast of ($0.65). Wedbush currently has a “Outperform” rating and a $12.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. Wedbush also issued estimates for PepGen’s Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.22) EPS, FY2026 earnings at ($2.11) EPS, FY2027 earnings at ($1.91) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at ($0.10) EPS.

Several other research analysts also recently issued reports on PEPG. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of PepGen in a research report on Monday, February 24th. Bank of America cut PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective on the stock. in a report on Monday, December 16th.

PepGen Price Performance

Shares of PepGen stock opened at $3.15 on Thursday. PepGen has a 1 year low of $1.16 and a 1 year high of $19.30. The company has a market capitalization of $102.68 million, a P/E ratio of -1.06 and a beta of 1.53. The business has a 50 day moving average price of $2.37 and a 200 day moving average price of $5.69.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.13.

Institutional Trading of PepGen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC grew its holdings in PepGen by 9.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock valued at $14,201,000 after buying an additional 140,000 shares during the period. Jane Street Group LLC grew its holdings in PepGen by 29.1% in the 3rd quarter. Jane Street Group LLC now owns 27,748 shares of the company’s stock valued at $237,000 after buying an additional 6,254 shares during the period. Barclays PLC grew its holdings in PepGen by 318.7% in the 3rd quarter. Barclays PLC now owns 21,971 shares of the company’s stock valued at $189,000 after buying an additional 16,723 shares during the period. JPMorgan Chase & Co. grew its holdings in PepGen by 289.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 26,611 shares of the company’s stock valued at $228,000 after buying an additional 19,786 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in PepGen by 331.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after buying an additional 1,794,641 shares during the period. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.